Drug
Nesuparib clinical trials
Also written JPI-547.
Keep track of what changes. Save the nesuparib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 1
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses nesuparib is read from its arms, and is right about nine times in ten.
Testing it · 6
- Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsNot yet recruitingPhase 1Onconic Therapeutics Inc.NCT07570186Written as JPI-547
- To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian CancerNot yet recruitingPhase 2Onconic Therapeutics Inc.NCT07370818Written as JPI-547
- To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric CancerNot yet recruitingPhase 1/2Onconic Therapeutics Inc.NCT07364422Written as JPI-547
- First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingPhase 2Yonsei UniversityNCT06502743Written as Nesuparib
- A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorActive, not recruitingPhase 2Onconic Therapeutics Inc.NCT05475184Written as JPI-547
- A Study of NOV140201 (JPI-547) in Subject With Advanced Solid TumorsCompletedPhase 1Onconic Therapeutics Inc.NCT04335604Written as JPI-547
Given in every arm · 1 — nesuparib is usual care beside what is tested
Codes
What other systems call nesuparib · ClinicalTrials.gg INT018092
- UNII (FDA) U6N7333GDWNESUPARIBOne source FDA
- NCI Thesaurus C187049NesuparibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U6N7333GDW | NESUPARIB | One source FDA |
| NCI Thesaurus | C187049 | Nesuparib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.